Arthur Klausner - JoVE Visualize

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Policies

Filters

Arthur Klausner

Showing results (1-10 of 5) with videos related to

Pageof 1

Sort By:

Nature Biotechnology|February 11, 2009

Charting a course through a perfect stormArthur Klausner

Nature Biotechnology|April 9, 2005

Biotech venture capital--it's not too late to be earlyArthur Klausner

Nature Biotechnology|October 8, 2005

Mind the (biomedical funding) gapArthur Klausner

Nature Biotechnology|February 12, 2022

So you want to start a biotech companySadhana Chitale, Colm Lawler, Arthur Klausner

Cancer Medicine|April 25, 2019

A phase II clinical study of 13-deoxy, 5-iminodoxorubicin (GPX-150) with metastatic and unresectable soft tissue sarcomaBrian A Van Tine, Mark Agulnik, Richard D Olson, et al.

Pageof 1

Search research articles

Showing results (1-10 of 5) with videos related to

Sort By:

Pageof 1

Nature Biotechnology|February 11, 2009

Charting a course through a perfect stormArthur Klausner

Nature Biotechnology|April 9, 2005

Biotech venture capital--it's not too late to be earlyArthur Klausner

Nature Biotechnology|October 8, 2005

Mind the (biomedical funding) gapArthur Klausner

Nature Biotechnology|February 12, 2022

So you want to start a biotech companySadhana Chitale, Colm Lawler, Arthur Klausner

Cancer Medicine|April 25, 2019

A phase II clinical study of 13-deoxy, 5-iminodoxorubicin (GPX-150) with metastatic and unresectable soft tissue sarcomaBrian A Van Tine, Mark Agulnik, Richard D Olson, et al.

Pageof 1